Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
The collaboration will establish the MUMPMP–Agilent BioDiscovery Hub
The company also revealed that MK-2214 has received Fast Track Designation from the U.S. Food and Drug Administration
The update reflects long-term clinical trial data showing that many patients with mCSCC or laCSCC experienced lasting responses
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
The trial tested six injectable doses and three oral doses over as long as 36 weeks
Data show adjuvant Verzenio plus endocrine therapy extends overall survival and sustains long-term improvements in invasive disease-free survival
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
